Keyphrases
In Cancer
63%
Patients with Cancer
62%
Cancer Patients
61%
Hepatitis C Virus
52%
Risk Factors
42%
Hepatitis C Virus Screening
39%
Clostridium Difficile Infection
39%
Tertiary Cancer Center
39%
COVID-19
33%
Sustained Virological Response
24%
Ribotyping
19%
Bronchoalveolar Lavage
19%
Immunocompromised Patients
19%
30-day Mortality
19%
Clinical Outcomes
19%
SVR12
19%
Direct-acting Antivirals
19%
Diagnostic Algorithm
19%
International multicenter Study
19%
Enzyme-linked Immunosorbent Assay (ELISA)
19%
Survivorship
19%
COVID-19 Inpatients
19%
Stem Cell Transplant Recipients
19%
Acute Hepatitis C
19%
Infection Management
19%
Treatment Modalities
19%
Direct-acting Antiviral Therapy
19%
Patient Relevance
19%
Response Rate
19%
Risk Impact
19%
Impact of Cancer
19%
Risk Treatment
19%
Histoplasmosis
19%
Ovarian Cancer
19%
Peritonitis
19%
Long COVID
19%
Malignancy
19%
Anti-hepatitis C Virus
17%
Electronic Health Records
17%
Nucleic Acid Amplification Test
14%
Post-acute Sequelae of SARS-CoV-2 Infection
14%
Nasopharyngeal Swab
13%
Cancer Therapy
13%
Drug Interactions
13%
Pibrentasvir
13%
Glecaprevir
13%
Ledipasvir
13%
Infected Patients
13%
Universal Screening
13%
Solid Tumors
11%
Medicine and Dentistry
Malignant Neoplasm
100%
COVID-19
59%
Infection
50%
Hepatitis C Virus
39%
Immunocompromised Patient
19%
Solid Organ Transplantation
19%
Enzyme Immunoassay
19%
Viral Respiratory Tract Infection
19%
Lung Lavage
19%
Stem Cell Transplant
19%
Postcovid Syndrome
19%
Diagnosis
19%
Peritonitis
19%
Histoplasmosis
19%
Ovarian Cancer
19%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
Cancer
17%
Nasopharyngeal Swab
13%
Nucleic Acid Amplification
13%
Sequela
10%
Electronic Health Record
9%
Cell Therapy
8%
Diseases
8%
Solid Malignant Neoplasm
7%
Polymerase Chain Reaction
6%
Remdesivir
6%
Recurrent Disease
6%
Lymphocytopenia
6%
Necrosis
6%
Rheumatoid Arthritis
6%
Inflammatory Arthritis
6%
Logistic Regression Analysis
6%
Prevalence
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
78%
Hepatitis C Virus
78%
Infection
27%
Solid Malignant Neoplasm
26%
Chronic Hepatitis C
24%
Antiviral Drug
22%
Viral Respiratory Tract Infection
19%
Immune Checkpoint Inhibitor
19%
Histoplasma
19%
Peritonitis
19%
Ovary Cancer
19%
Histoplasmosis
19%
Antiviral Therapy
14%
Adverse Event
14%
Drug-Drug Interaction
9%
Glecaprevir Plus Pibrentasvir
9%
Ledipasvir Plus Sofosbuvir
9%
SARS Coronavirus
8%
Observational Study
7%
Prednisone
6%
Upper Respiratory Tract Infection
6%
Rhinovirus
6%
Inflammatory Arthritis
6%
Necrosis
6%
Rheumatoid Arthritis
6%
Hepatitis C Virus Genotype 1
6%